1) Barone P, Scarzella L, Marconi R, et al:Pramipexole versus sertraline in the treatment of depression in Parkinson's disease:A national multicenter parallel-group randomized study. J Neurol 253:601-607, 2006
2) Barone P:Treatment of depressive symptoms in Parkinson's disease. Eur J Neurol 18 (Suppl 1):S11-S15, 2011
3) Braak H, Rub U, Gai WP, et al:Idiopathic Parkinson's disease:Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110:517-536, 2003
4) Frisina PG, Haroutunian V, Libow LS:The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat Disord 15:144-148, 2009
5) 岩本邦弘,尾崎紀夫:Mirtazapineのうつ病治療における可能性.臨床精神薬理 12:1779-1786, 2009
6) Jellinger KA:Neuropathological correlation of mental dysfunction in Parkinson's disease:An update. In:Wolter ECH, Schulten PH, Berendese HW, ed. Mental Dysfunction in Parkinson's disease Ⅱ. Academic Pharmaceutical Productions, Utrecht, pp82-105, 1999
receptor activation. Brain Res Bull 63:237-241, 2004
8) Menza M, Dobkin RD, Marin H, et al:A controlled trial of antidepressents in patients with Parkinson disease and depression. Neurolory 72:886-892, 2009
9) 水野美邦,近藤智善:よくわかるパーキンソン病のすべて.改訂第2版.永井書店,2011
10) Ramy P, Doder M, Lees A, et al:Depression in Parkinson's disease:Loss of dopamine and noradrenaline innervation in the limbic system. Brain 128:1314-1322, 2005
11) Weiser R, Hernadez-Rojas J, Flores J, et al:Efficacy, tolerability and safety of mirtazapine in the treatment of major depressive disorder due to Parkinson disease. Mov Disord 19(Supple 9):S205, 2004
12) Schrag A, Jahanshahi M, Quinn N:What contributes to quality of life in patients with Parkinson's disease? J neurol Neurosurg Psychiatry 69:308-312, 2000
13) The Global Parkinson's Disease Survey Steering Committee:Factors impacting on quality of life in Parkinson's disease:Results from an international survey. Mov Disord 17:60-67, 2002
14) Wermuth D, Morales KH, Moberg PJ, et al:Antidepressant studies in Parkinson's disease:A review and meta-analysis. Mov Disord 20:1161-1169, 2005
15) Zwarow C, Lyness MA, Mortimer JA, et al:Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60:337-341, 2003